How much does Adagraxibu cost in Hong Kong?

Adagrasib (Adagrasib) is a KRASG12C inhibitor that irreversibly and selectively binds to KRAS G12C, locking it in an inactive state. In the Phase 1-1b portion of the KRYSTAL-1 Phase 1-2 study, adagrasiib demonstrated clinical activity with an acceptable adverse event profile. Despite advances in the treatment of NSCLC, there are few effective treatment options for patients with KRAS G12C-mutated NSCLC.

Similar to sotorasib, adagrasib is a selective covalent inhibitor of KRASG12C; however, reported molecular pharmacology differences are : The drug half-life of sotorasib is 5 hours compared to 23 hours for adagrasib; adagrasib has a dose-dependent prolonged exposure and potential CNS penetration. In patients with advanced KRAS G12C mutated non-small cell lung cancer, the objective response rate of treatment with adagrasiib was 429%, the median duration of response was 85 months, the median progression-free survival was 65 months, and the median overall survival was 126 months. Adagrasiib showed evidence of clinical efficacy in most subgroups defined by baseline characteristics, including patients with CNS metastases, and in most molecular correlates.

Becauseadagrasibthe original drug has not yet been launched in China, and this drug is not sold in Hong Kong, and there is no price for this drug. The American original research version of adagrasib currently sold overseas, specifications200mg*180 tablets, is priced at hundreds of thousands of yuan per box (the price may fluctuate due to exchange rate effects), which is very expensive. Currently, there are no generic drugs of adagrasib produced overseas. For more drug information and specific prices, please consult Yaode’s medical consultant.